LifeCycle Pharma initiates clinical trials of its first product  

2004.10.06
The Danish biotech company has initiated clinical trials of its first product, an improved formulation of fenofibrate, a drug used for lowering cholesterol

Biotech company LifeCycle Pharma has initiated clinical trials of its first product, an improved tablet formulation of fenofibrate, a drug used for lowering cholesterol. The registration application for the drug is expected to be filed in 2005 with launch slated for 2006. Michael Wolff Jensen, finance director of LifeCycle Pharma, says that the company's formulation makes the drug more convenient for patients, since it does not have to be taken together with food.

 

Sales of fenofibrate worldwide amounted to DKK 4.8 bn (USD 800 mn) in 2003, and continues to show strong growth. LifeCycle Pharma expects that it will be able to take a 25% market share relatively quickly following launch.

 

LifeCycle Pharma is located in Hørsholm, north of Copenhagen. It is a spin-off of pharmaceutical company H. Lundbeck. LifeCycle Pharma has developed a clinically validated drug delivery platform for solving the insufficiencies of drugs with low water solubility, thus improving the bioavailability of marketed drugs and NCEs. The news is reported by financial newspaper Børsen online and on LifeCycle Pharma's website.

 

Link > LifeCycle Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×